CStone Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
CStone Pharmaceuticals has a total shareholder equity of CN¥315.0M and total debt of CN¥363.2M, which brings its debt-to-equity ratio to 115.3%. Its total assets and total liabilities are CN¥1.2B and CN¥876.9M respectively.
Key information
115.29%
Debt to equity ratio
CN¥363.20m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥690.10m |
| Equity | CN¥315.04m |
| Total liabilities | CN¥876.86m |
| Total assets | CN¥1.19b |
Recent financial health updates
Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load?
Dec 12
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Recent updates
CStone Pharmaceuticals' (HKG:2616) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 26What CStone Pharmaceuticals' (HKG:2616) 33% Share Price Gain Is Not Telling You
Jul 07Shareholders May Not Be So Generous With CStone Pharmaceuticals' (HKG:2616) CEO Compensation And Here's Why
Jun 18CStone Pharmaceuticals' (HKG:2616) 35% Price Boost Is Out Of Tune With Revenues
May 23Revenues Working Against CStone Pharmaceuticals' (HKG:2616) Share Price Following 35% Dive
Apr 08Analysts Are More Bearish On CStone Pharmaceuticals (HKG:2616) Than They Used To Be
Apr 01There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 28% Share Price Rise
Feb 14Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load?
Dec 12There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise
Oct 04Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified
May 12Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%
Oct 04Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Financial Position Analysis
Short Term Liabilities: 2616's short term assets (CN¥901.5M) exceed its short term liabilities (CN¥625.8M).
Long Term Liabilities: 2616's short term assets (CN¥901.5M) exceed its long term liabilities (CN¥251.1M).
Debt to Equity History and Analysis
Debt Level: 2616 has more cash than its total debt.
Reducing Debt: 2616's debt to equity ratio has increased from 1.2% to 115.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2616 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2616 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 05:27 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CStone Pharmaceuticals is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |
| Hanyang Huang | Industrial Securities Co. Ltd. |
| Jing Ma | Jefferies LLC |